Germline Variants in Angiogenesis-Related Genes Contribute to Clinical Outcome in Head and Neck Squamous Cell Carcinoma.

Fibroblast growth factor (FGF)/FGF receptor (FGFR), and platelet-derived growth factor (PDGF)/PDGF receptor (PDGFR) systems, as well as some matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), are involved in various steps of angiogenesis. Data indicate that common germline variations in angiogenesis-regulating genes may modulate therapy results and cancer progression. However, whether these variants affect clinical outcome in head and neck squamous cell carcinoma (HNSCC) is unclear. Hence, we assessed the relationship between FGF/FGFR, PDGF/PDGFR, MMP, and TIMP genetic variants and treatment outcomes in HNSCC patients receiving radiotherapy (RT) alone or combined with cisplatin-based chemotherapy. In multivariate analysis, rs1048201 CC homozygotes showed a higher risk of death ( = 0.039), while rs2228230 T was strongly associated with an increased risk of locoregional relapse (HR 2.49, = 0.001) in the combination treatment subgroup. In the RT alone subset, rs243865 TT carriers had a higher risk of locoregional recurrence (HR 2.92, = 0.019), whereas rs246395 CC homozygotes were at increased risk of metastasis (HR 3.06, = 0.041). The rs7201 C and rs7501477 T were associated with a risk of locoregional failure in the entire cohort ( = 0.032 and 0.045, respectively). Furthermore, rs1048201, rs2228230, rs246395, rs243865, rs7201, and rs7201/rs7501477 were independent indicators of an unfavorable outcome. This study demonstrates that the , , , and variants may contribute to treatment failure and poor prognosis in HNSCC.